Oncology Pharmacy Specialty Home Study Syllabus for Recertification: Module 1A-B (Cert # L219167)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 02/24/2021
Content Release Date: 03/24/2021
Expiration Date: 09/28/2021
Activity Type: Application-based
CE Credits: 8.0 hours (BPS and ACPE)
Activity Fee: $160 (ASHP member); $215 (non-member)

Accreditation for Pharmacists

American Society of Health-System Pharmacists and the American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

Target Audience

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

  • Multiple Myeloma
  • Practice Management
  • Upper GI
  • Breast Cancer
  • Cancer-Related Infectious Diseases
  • Chronic Leukemia
  • Melanoma
  • Pediatrics

Activity Overview

The Home Study Syllabus is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice. 

Learners will be required to review the content of the articles and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by the BPS.  

For full program information, please visit: http://rxcertifications.org

Recertification Credit*

Board certified pharmacists are eligible to receive up to 8.0 hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity

ACPE Number

Credit Hours

*Assessment Pass Point

Oncology Home Study Syllabus Module 1A: Breast Cancer, Multiple Myeloma, Oncology Practice Management, and Gastric Cancer  

0204-9999-21-981-H01-P

4.00

80%

Oncology Home Study Syllabus Module 1B: Chronic Leukemia, Melanoma, Pediatric Malignancy, Cancer-related Infectious Diseases  

0204-9999-21-982-H01-P

4.00

80%


Articles and Learning Objectives

Oncology Home Study Syllabus Module 1A: Breast Cancer, Multiple Myeloma, Oncology Practice Management, and Gastric Cancer
0204-9999-21-981-H01-P

Belantamab mafodotin for relapsed or refractory multiple myeloma

Lonial S, Lee HC, Badros A et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020; 21:207-21.

Learning Objectives:

  • Apply the findings of the DREAMM-2 study to patients with relapsed or refractory multiple myeloma.
  • Use patient-specific clinical data to formulate appropriate treatment and monitoring parameters for patients with relapsed or refractory multiple myeloma.
  • Summarize the newly established REMS (risk evaluation and mitigation strategies) regulations and standards based on the adverse effect profile of belantamab mafodotin-blmf.
Approved Risk Evaluation and Mitigation Strategies (REMS): Blenrep (belantamab mafodotin)

U.S. Food & Drug Administration (FDA). Approved Risk Evaluation and Mitigation Strategies (REMS): Blenrep (belantamab mafodotin). Updated September 2020. 

Learning Objectives:

  • Apply the findings of the DREAMM-2 study to patients with relapsed or refractory multiple myeloma.
  • Use patient-specific clinical data to formulate appropriate treatment and monitoring parameters for patients with relapsed or refractory multiple myeloma.
  • Summarize the newly established REMS (risk evaluation and mitigation strategies) regulations and standards based on the adverse effect profile of belantamab mafodotin-blmf.

Dillmon MS, Kennedy EB, Anderson MK et al. Patient-centered standards for medically integrated dispensing: ASCO/NCODA standards. J Clin Oncol. 2019; 38:633-44.

Learning Objectives:

  • Interpret patient-centered practice standards for outpatients who have been prescribed oral anticancer drugs or supportive care medications in the setting of medically integrated dispensing.
  • Assess evidence-based tools and resources for the dispensing of oral anticancer drugs in the outpatient setting.
  • Evaluate the impact of various interventions for patients receiving oral anticancer drugs in the outpatient setting.

Shitara K, Bang YJ, Iwasa S et al.; for the DESTINY-Gastric01 Investigators. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020; 382:2419-30.

Learning Objectives:

  • Evaluate the outcomes of the DESTINY-Gastric01 trial in patients with advanced gastric or gastroesophageal junction (GEJ) cancers.
  • Design a supportive care plan for patients with advanced gastric or GEJ cancers receiving trastuzumab deruxtecan.
  • Summarize the differences between trastuzumab deruxtecan and other HER2-directed therapies for use in patients with advanced gastric or GEJ cancers.

 Modi S, Saura C, Yamashita T et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020; 382:610-21.

Learning Objectives:

  • Choose appropriate pharmacotherapy for individual patients based on the results of the DESTINY-Breast01 trial.
  • Evaluate potential adverse effects and monitoring strategies for patients receiving fam-trastuzumab deruxtecan-nxki.
  • Analyze efficacy and safety data for the use of fam-trastuzumab deruxtecan-nxki to treat patients with refractory HER2-positive metastatic breast cancer.

Oncology Home Study Syllabus Module 1B: Chronic Leukemia, Melanoma, Pediatric Malignancy, Cancer-related Infectious Diseases
0204-9999-21-982-H01-P

Drayson MT, Bowcock S, Planche T et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2019; 20:1760-72.

Learning Objectives:

  • Evaluate the outcomes of the TEAMM trial in patients with newly diagnosed myeloma.
  • Assess patients with myeloma to determine whether they are eligible for prophylaxis with levofloxacin according to the TEAMM trial.
  • Design an appropriate patient-specific management and monitoring plan for levofloxacin prophylaxis in patients with newly diagnosed myeloma based on the procedures and results of the TEAMM trial.

Shanafelt TD, Wang XV, Kay NE et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019; 381:432-43.

Learning Objectives:

  • Interpret trial design, efficacy and safety data for a pharmacotherapy regimen for the treatment of chronic lymphocytic leukemia.
  • Select appropriate pharmacotherapy based on genomic test results in a patient with chronic lymphocytic leukemia.
  • Devise appropriate plans for preventing, monitoring, and treating adverse reactions associated with a pharmacotherapy regimen for the treatment of chronic lymphocytic leukemia.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing in a patient with chronic lymphocytic leukemia.

Warner AB, Palmer JS, Shoushtari AN et al. Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. J Clin Oncol. 2020; 38:1655-63.

Learning Objectives:

  • Apply the outcomes of the Warner et al. trial to patients with melanoma whose treatment plan includes anti–PD-1 therapy.
  • Summarize the strengths and weaknesses of the design and methods employed by the Warner et al. trial.
  • Counsel patients with advanced melanoma on the long-term outcomes of immune checkpoint inhibitor therapy.

Getz KD, Sung L, Alonzo TA et al. Effect of dexrazoxane on left ventricular systolic function and treatment outcomes in patients with acute myeloid leukemia: a report from the Children’s Oncology Group. J Clin Oncol. 2020; 38:2398-406.

Learning Objectives:

  • Design a patient-specific treatment and monitoring plan for the use of dexrazoxane in children and young adults with acute myeloid leukemia.
  • Identify and manage the potential toxicities associated with modern treatment regimens for pediatric and young adult patients with acute myeloid leukemia.
  • Interpret the efficacy and safety results of the Getz, et al study evaluating dexrazoxane in pediatric acute myeloid leukemia.

Planners, Presenters and Reviewers

Clinical Pharmacy Specialist, Acute Care Malignant Hematology
UNC Medical Center
Chapel Hill, NC

Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, UT

Assistant Professor of Pharmacy Practice
Dusquesne University School of Pharmacy
Pittsburgh, PA

Clinical Manager - Oncology Pharmacy
Indiana University Health
Indianapolis, IN 

Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, NY

Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, PA

Associate Member, Personalized Medicine Specialist
DeBartolo Family Personalized Medicine Institute
H. Lee Moffitt Cancer Center
Tampa, FL

Clinical Pharmacy Specialist - Pediatric Oncology
Cincinnati Children's Hospital Medical Center
Cincinnati, OH

*Content Matter Experts

Angela T. Cassano, Pharm.D., BCPS, FASHP
Susan R. Dombrowski, M.S., R.Ph.

Eslam Fouad Abdelbaky, BCPS, BCOP, BCMAS
Robert Appell, Pharm.D., BCOP
Cynthia Burns, RPh, Pharm.D., BCOP
Cathy Cao, Pharm.D., BCOP
Soniya Chandrasekhara, Pharm.D.
Kelly Chillari, Pharm.D., BCOP
Eunah Cho, Pharm.D., BCOP
Phuong Dao, Pharm.D., BCOP
Bryan Do, Pharm.D., BCOP
Jennifer Espiritu, Pharm.D., BCOP
Alan Fisher, Pharm.D., BCOP
Sara Fleszar, Pharm.D., BCOP
Frank Gentile, Pharm.D., BCOP
Shawn Griffin, Pharm.D., BCOP
Derick Gross, Pharm.D., M.S., BCPS, BCOP
Benjamin Gruseck, Pharm.D., BCOP
Michael Harada, Pharm.D., BCOP
Elisabeth Hébert, B.Pharm., M.Sc., BCOP
Jennifer Hering, Pharm.D., M.S., BCOP, BCSCP
Jerline Hsin, Pharm.D., BCPS, BCOP
Anna Jan, Pharm.D., BCOP
Austin Jenkins, Pharm.D., BCOP
Brittany Jensen, Pharm.D., BCOP
Stephen Kaurala, Pharm.D., BCOP
Sidney Keisner, Pharm.D., BCOP
Polly Kintzel, Pharm.D., BCPS, BCOP
Tiffany Knoll, Pharm.D., M.S., BCOP
Lesli  Lavery, Pharm.D., BCOP, CPP
Jessie Lawton, Pharm.D., BCOP
Whitney  Lewis, Pharm.D., BCOP
Yemag Limay, Pharm.D., BCOP
Claire Mach, Pharm.D., BCOP
Jonathan Malara, Pharm.D., BCOP
Kathryn McKitrick, Pharm.D., BCOP
Donald Moore, Pharm.D., BCPS, BCOP, DPLA
Rachael Morgan, Pharm.D., BCOP
Jennifer Ng, Pharm.D., BCACP, BCOP
Carolyn Oxencis, Pharm.D., BCOP
Carol Peek, BSPharm, Pharm.D.
Amy Riedel, Pharm.D., BCPS, BCOP
Brenna Rowen, Pharm.D., BCOP
Joslyn Rudoni, Pharm.D., BCOP
Josephine  Sasu-Tenkoramaa, Pharm.D., BCOP
Gianni Scappaticci, Pharm.D., BCOP
Samantha Shi, Pharm.D., BCOP
Sunao Slayton, Pharm.D., BCOP
Anne Spengler, Pharm.D., BCOP
Carol Stadler, Pharm.D., BCOP
Lindsay Stansfield, Pharm.D., BCPS, BCOP
Cody Steeves, Pharm.D., BCOP
Violette Sun-Basorun, Pharm.D., M.B.A., BCOP
Kelly Tammaro, Pharm.D., BCOP
Carissa Treptow, Pharm.D., BCOP
Vivian Tsang, Pharm.D., BCOP, BCPS
Sheng Fan Wang, Ph.D., BCOP
Chen Xu, Ph.D., BCOP
Lily Yan, Pharm.D., BCOP
Barbara Yim, Pharm.D., BCOP

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP and ACCP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP and ACCP education activities are qualified and selected by ASHP and ACCP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Karen Fancher is Consultant, AstraZeneca, LP; Consultant, Merck & Co. 

All other planners, presenters, reviewers, ASHP and ACCP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Methods and CE Requirements

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 

Development

These activities were developed by ASHP and ACCP.